Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.

Pharmacogenomics - 1 Apr 2016

Altmann Vivian, Schumacher-Schuh Artur F, Rieck Mariana, Callegari-Jacques Sidia M, Rieder Carlos R M, Hutz Mara H

Abstract excerpt

AIM: Levodopa is first-line treatment of Parkinson's disease motor symptoms but, dose response is highly variable. Therefore, the aim of this study was to determine how much levodopa dose could be explained by biological, pharmacological and genetic factors. PATIENTS & METHODS: A total of 224 Parkinson's disease patients were genotyped for SV2C and SLC6A3 polymorphisms by allelic discrimination assays....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antiparkinson Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Levodopa

Share to Membrane Glycoproteins

Share to Nerve Tissue Proteins

Share to Parkinson Disease

Share to Sex Factors

Source

Identifiers

PMID: 27019953
DOI: 10.2217/pgs.15.183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.PMID 27019953Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?Semantic proximity Read ↗

Parkinson’s Disease Pharmacogenomics: New Findings and PerspectivesSemantic proximity Read ↗

Anti-Parkinson's disease drugs and pharmacogenetic considerationsSemantic proximity Read ↗

Pharmacogenetics and levodopa induced motor complicationsSemantic proximity Read ↗

Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.Semantic proximity Read ↗

Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.Semantic proximity Read ↗

The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.Semantic proximity Read ↗

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.Semantic proximity Read ↗

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.Semantic proximity Read ↗

[Pharmacogenetics in Parkinson's disease treatment].Semantic proximity Read ↗

MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.